Igenomedx INC.

Igenomedx INC. was paid $2.25M by Medicaid between Feb 2018 and Dec 2024, across 44 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 45% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Texas

Rank by total paid#39 of 436

Median peer was paid$17K

This provider vs. median130×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	222	$5K
2019	474	$520.00
2020	4,003	$153K
2021	25,430	$689K
2022	44,294	$961K
2023	19,023	$300K
2024incomplete	7,575	$138K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	45%	16,987	12,601	$1.00M
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	13%	4,189	3,445	$284K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	12%	14,964	11,346	$269K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	6.5%	8,284	6,318	$145K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	5.8%	8,615	7,172	$131K
87640		1.8%	7,102	6,027	$41K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	1.6%	1,990	1,909	$37K
87498		1.6%	5,409	4,609	$37K
87541		1.3%	4,536	3,797	$30K
87481		1.2%	2,117	1,832	$27K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	1.1%	346	341	$25K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	1.1%	505	411	$25K

32 more codes

87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	1.0%	344	$23K
87581		1.0%	5,356	$23K
87486		<1%	5,341	$22K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	1,302	$21K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	3,057	$20K
87631		<1%	848	$20K
87653		<1%	2,206	$9K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	448	$8K
81225		<1%	313	$7K
81227		<1%	298	$6K
81226		<1%	361	$5K
87507		<1%	219	$4K
87500		<1%	1,340	$4K
87641		<1%	1,350	$4K
81401		<1%	341	$3K
81335		<1%	283	$3K
81328		<1%	282	$2K
81230		<1%	282	$2K
81241		<1%	301	$2K
81231		<1%	267	$2K
81240		<1%	300	$2K
81291		<1%	301	$1K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	418	$1K
87150		<1%	85	$32.75
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	0%	165	$0.00
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	0%	19	$0.00
87563		0%	19	$0.00
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	0%	19	$0.00
87505		0%	56	$0.00
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	0%	19	$0.00
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	0%	18	$0.00
87511		0%	19	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialVANEE, NITI (CEO & PRESIDENT)